Loading patent…
AssigneeNational Yang Ming Chiao Tung University
InventorsNien-Jung Chen, Chien-Jung Li
Estimating the term…
The present invention provides a recombinant multivalent TREM1 agonist, termed Tetra-CNX, designed to engage and activate TREM1 on myeloid cells. The ligand comprises multiple calnexin luminal domains assembled in a multimeric configuration, enabling high-avidity receptor binding and downstream SYK-dependent signaling. Upon activation, Tetra-CNX enhances lysosomal remodeling and promotes efficient antigen uptake, processing, and presentation via MHC class I and II pathways. This invention enables improved priming of CD4+ and CD8+ T cells and facilitates immune activation in contexts requiring enhanced antigen presentation, including but not limited to cancer, infectious diseases, and vaccine responses. Pharmaceutical compositions and methods of use are provided for modulating myeloid cell function and adaptive immunity through TREM1-targeted intervention.
A composition comprising a recombinant TREM1 agonist ligand, wherein the recombinant TREM1 agonist ligand comprises a luminal domain in a calnexin assembled capable of binding and activating TREM1 on myeloid cells.
Dependencies are inferred from the claim text.